Alteogen Inc.
196170
Rang in aandelen
#1836
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Aandeelprijs
$165.61
Marktkapitalisatie
$11.53B
Verandering (1 dag)
4.13%
Verandering (1 jaar)
-46.48%
Land
KR
Handel Alteogen Inc. (196170)
Categorie
Healthcare
Aandelsplitsingen voor Alteogen Inc. (196170)
Het aandeel Alteogen Inc. (symbool: 196170) heeft in totaal 5 splitsingen ondergaan.
De meest recente splitsing vond plaats op Aug 05, 2026.
Eén aandeel 196170 dat vóór Dec 07, 2017 werd gekocht, staat nu gelijk aan 1.2037037037037 aandelen 196170.
De meest recente splitsing vond plaats op Aug 05, 2026.
Eén aandeel 196170 dat vóór Dec 07, 2017 werd gekocht, staat nu gelijk aan 1.2037037037037 aandelen 196170.
Lijst van aandelen splitsingen
| Jaar | Splitsing | Vermenigvuldiging | Cumulatieve vermenigvuldiging |
|---|---|---|---|
| 2026-08-05 | 13:10 | x1.3 | x1.2037037037037 |
| 2022-10-25 | 6:5 | x1.2 | x0.92592592592593 |
| 2021-03-24 | 5:4 | x1.25 | x0.77160493827161 |
| 2020-07-23 | 10:9 | x1.1111111111111 | x0.61728395061728 |
| 2017-12-07 | 5:9 | x0.55555555555556 | x0.55555555555556 |
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aantal aandelen splitsingen | Cumulatieve vermenigvuldiging | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
